Abstract: The present invention relates to a means of dialysis for removing protein-bound substances from a biological fluid, especially blood or blood plasma, which contains at least one means for solubilizing protein-binding substances to be removed into the biological fluid and/or dialysis fluid, and to a process for removing protein-bound substances from a biological fluid.

Abstract: Technology for preparing a dialysis fluid capable of flexibly changing bicarbonate ion concentration and maintaining concentrations of electrolytes such as potassium, calcium, and magnesium at constant levels during dialysis according to the disease state of a patient. A three-component dialysate containing an agent S containing sodium chloride, an agent B containing sodium bicarbonate, and an agent A containing electrolyte components other than sodium chloride and sodium bicarbonate, with suitable adjustment of the amount of the agent B during dialysis fluid preparation maintains concentrations of trace metal ions such as potassium ions, calcium ions, and magnesium ions in a dialysis fluid at constant levels and flexibly changes the bicarbonate ion concentration therein. Adjusting the ratio between the amount of the agent S and agent B when the dialysate is used also makes it possible to maintain the sodium ion concentration at a constant level or flexibly change the sodium ion concentration.

Abstract: An extracorporeal blood processing method using a blood circuit comprising a pair of blood passages attached to opposite flow ends of a blood treatment device and said blood circuit is mounted on a blood pump console, the method includes: withdrawing blood from a vascular system of a human patient and drawing the blood into the blood circuit; pumping the withdrawn blood through one of the pair of blood passages using a first blood pump of the console and into the blood treatment device; pumping the treated blood from the treatment device through the other of the pair of blood passages using a second blood pump of the console; infusing the treated blood from the other blood passage and into the vascular system of the patient, and periodically reversing a flow direction of blood through the pair of blood passages and blood treatment device.

Abstract: The present invention is a peritoneal function testing method characterized by using a ratio MTACun/MTACc calculated using MTACun and MTACc as an index for a peritoneal function test, where MTACun is an overall mass transfer-area coefficient for urea nitrogen and MTACc is an overall mass transfer-area coefficient for creatinine. The use of MTACun/c of the present invention in this way enables examination of the future peritoneal function of a patient (a mechanism of deterioration in peritoneal function). To be specific, MTACun and MTACc can be obtained by computing Pyle-Popovich model. In addition, the peritoneal function testing method may further calculate a permeability coefficient for cell pores (LPSC) and an overall permeability coefficient (LPS) from Three-Pore Theory model while obtaining a ratio LPSC/LPS calculated using the LPSC and the LPS, and may use the LPSC/LPS ratio and the MTACun/MTACc ratio as indexes for the peritoneal function test.

Abstract: A peritoneal function testing method uses a ratio of MTACun/MTACc, calculated using MTACun and MTACc, as an index for a peritoneal function test, wherein MTACun is an overall mass transfer-area coefficient for urea nitrogen and MTACun is an overall mass transfer-area coefficient for creatinine. The use of MTACun/MTACc enables examination of the future peritoneal function of a patient (a mechanism of deterioration in peritoneal function). To be specific, MTACun and MTACc can be obtained by computing a Pyle-Popovich model. In addition, the peritoneal function testing method further calculates a permeability coefficient for cell pores (LpSC) and an overall permeability coefficient (LPS) from a Three-Pore Theory model while obtaining a ratio of LPSC/LPS calculated using the LPSC and the LPS. The LPSC/LPS ratio and the MTACun/MTACc ratio can be used as indexes for the peritoneal function test.

Abstract: Dialysis apparatus including a blood treatment unit having a dialysate chamber and a blood chamber separated by a semipermeable membrane, a dialysate circuit presenting a supply line and a discharge line connected to the blood treatment unit, a preparation device for preparing a dialysate containing a substance present in the blood too and a regulator regulating the concentration of the substance in the dialysate. A blood circuit to circulate extracorporeal blood through the blood chamber; a controller that determines a value representative of the concentration of the substance in the blood and are programmed for driving the regulator as a function of the determined value representative of the substance concentration in the blood such that the substance concentration in the dialysate tends towards the substance concentration in the blood.

Abstract: The present invention relates to a method for controlling a filtration rate during treatment of a body fluid, e.g., during hemofiltration or dialysis, comprising the steps of defining a target relation, or a development during dialysis thereof, between one or more calculated or measured value(s) reflecting the mass, concentration, or the volume of a substance comprised by a patient's tissue or bodily fluid, and one or more calculated or measured value(s) reflecting a patient's distribution space or an approximation thereof; during dialysis repeatedly calculating or measuring value(s) reflecting the mass, concentration or the volume of the substance and/or reflecting the distribution space or an approximation thereof, and determining the relation therebetween at least once; and controlling the filtration rate of the body fluid treatment device such that the determined relation is or approaches the target relation.

Abstract: A combination of acid zirconium phosphate and alkaline hydrous zirconium oxide are utilized as ion-exchange materials, for example, in sorbent dialysis. The combination provides for dialysate regeneration while maintaining constant and controlled levels of Na+, HCO3?, and pH.

Abstract: A medical dialysis system including a filtration system configured to filter a water stream, a water purification system configured to purify the water stream in a non-batch process, a mixing system, and a dialyzer system. The mixing system includes a supply of dialysate components, a conductivity sensor positioned within a fluid pathway through which the water stream flows, and a control mechanism having a pump configured to control an amount of the one or more dialysate components added to the water stream from the supply. The mixing system can produce a stream of dialysate from mixing the one or more dialysate components with the water stream in a non-batch process. The dialyzer system includes a dialyzer, a plurality of pumps capable of pumping the stream of dialysate across the dialyzer, and another conductivity sensor positioned downstream of the dialyzer within a fluid pathway through which the water stream flows.

Abstract: Blood treatment system and method for high rate hemofiltration ensures against pyrogenic patient reaction by providing various mechanisms for filtering replacement fluid to remove endotoxins and other safety features including detecting incorrect fluid administration.

Abstract: The invention covers a cartridge for use in a hemodialysis machine, the cartridge comprising a dialysate flow path including a dialyzer, the dialysate flow path for delivering a flow of dialysate through the dialyzer; a mixing pump defining a chamber having volume variable between a maximum volume and a minimum volume for receiving a predetermined volume of a first dialysate solution base, second dialysate solution base, and a volume of water; a first dialysate solution base supply conduit having a first positive displacement pump having a first inlet valve and a first outlet valve associated therewith; a second dialysate solution base supply conduit having a second positive displacement pump having a second inlet valve and a second outlet valve associated therewith; a first and second fluid conduit associated joining respective first and second positive displacement pumps with the mixing pump; and a third fluid conduit for connecting the mixing pump outlet to a dialyzer filter inlet.

Abstract: The present invention relates to a method of treating anemia especially in an EPO resistant hemodialysis patient, comprising hemodialysis with a high cut-off dialysis membrane, wherein the hemodialysis membrane is characterized in that it has a molecular weight cut-off in water, based on dextran sieving coefficients, of between 90 and 200 kD and a molecular weight retention onset in water, based on dextran sieving coefficients, of between 10 and 20 kD, and a ?MW of between 90 and 170 kD. The invention further relates to a high cut-off hemodialysis membrane for the treatment of anemia in hemodialysis patients, especially EPO resistant hemodialysis patients.

Abstract: A peritoneal function testing apparatus tests the peritoneal function of a dialysis patient easily and with high accuracy. Standards of four kinetic parameters (CCr, Kt/V, MTACu, and MTACc) available in a definite dialysis guideline are computed in accordance with a relational expression, and a curve showing the relation between MTACu/c and the drained fluid volume is indicated in a graph together with the PET data of the patient which has been prepared separately. Thus, the peritoneal function can be evaluated based on the relative position of the patient's data and the curve showing the standard values in the graph.

Abstract: Methods include monitoring indicators of blood pH or blood electrolyte levels during a blood fluid removal session and adjusting concentrations of pH buffers or electrolytes in dialysate or replacement fluid used during the session based on the monitored indicators. Blood fluid removal systems may employ sensors that monitor blood pH or electrolyte levels to adjust the fluid parameters during a blood fluid removal session.

Abstract: A dialysis device for operation in multiple modes and for maintaining a known gradient of potassium ion or other electrolyte between the blood of a patient and a dialysate fluid is described. The dialysis device is capable of being used for hemodialysis or peritoneal dialysis, and the dialysis device is capable of operation with a dialysate purification unit outside of a clinical setting or with a supply of water that can be supplied in a clinical setting. The dialysis device has a composition sensor containing a potassium-sensitive electrode for measuring a potassium ion concentration in one or more of the patient's blood and the dialysate fluid and an infusate pump operated to adjust a potassium ion concentration in the dialysate fluid based at least in part on data from the composition sensor.

Abstract: The present invention relates to a method of adapting of a second threshold window of at least a second measured variable depending on the change of a first threshold window of a first measured variable, wherein the adaptation is performed by the use of a control unit having been provided and/or configured therefor. The present invention further relates to a control device, a medical treatment apparatus, a medical monitoring apparatus, a digital storage means, a computer program product and a computer program.

Abstract: The invention relates to a device and a method for conveying a fluid to a filter unit of a medical treatment apparatus, in particular for conveying a dialysing fluid to a treatment unit, in particular a dialyser or filter of an extracorporeal blood treatment apparatus. The device comprises a balancing unit and a recirculation unit, which comprises one or more chambers. With the balancing unit, it is possible to supply fresh fluid continuously to the recirculation circuit and to discharge used fluid from the recirculation circuit. The supply and discharge of fresh and used dialysing fluid can take place at a flow rate other than the flow rate at which the fluid circulates in the recirculation circuit via the filter unit.

Abstract: A medical apparatus comprises a control system allowing storage of a number of shaping profiles. Each shaping profile is stored as a plurality of pairs, including a shaping profile reference value and a time interval value. The reference value is represented as fraction, for instance a percentage, of the total weight loss the apparatus should achieve at the end of a treatment time. Each time interval value is represented either as fraction of the total treatment time or as a prefixed actual time interval. The control system calculates the actual weight loss rate versus time profile based on the desired total weight loss, on the desired total treatment time as well as on selected desired shaping profile.

Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: An apparatus and a method for monitoring the supply of replacement fluid during an extracorporeal treatment of blood is disclosed. Detection of the supply of replacement fluid upstream or downstream of the dialyser or filter is based on a measurement of the optical or physical density of the blood or of a constituent of blood in the extracorporeal circulation. To detect pre- or post-dilution, the blood flow rate and/or the replacement rate and/or the flow rate of the fluid removed from the blood through the dialyser membrane is altered, and the density of the blood or of the constituent of blood is measured upstream and/or downstream of the dialyser. Additionally, an apparatus for treating blood with an apparatus for monitoring the supply of replacement fluid is disclosed.

Abstract: A method for batch implementation of settings in a renal replacement therapy device including: displaying on a user interface control settings which may be manually selected by an operator; selecting an independent control setting of the plurality of control settings; adjusting the independent control setting to an independent control setting level selected by an operator; temporarily storing the adjusted independent control setting level; automatically adjusting a dependent control setting level based upon the independent control level; displaying the adjusted independent control setting level and the adjusted dependent control setting, and implementing both the adjusted independent control setting level and the adjusted dependent control setting to control the device, by actuating a batch setting acceptance operation.

Abstract: A method for preparing a blood component composition for reducing risk of transfusion related injury includes passing a blood component composition through a tangential flow filter unit comprising one or more filter membranes. A diafiltration solution is added to the blood component composition during the filtration process. Non-cellular plasma components, including antibodies, are removed from the blood component composition by the tangential flow filtration.

Abstract: Phosphate depletion, a physiological condition commonly seen in certain patient populations, including alcoholics, malnourished, acutely ill patients, patients receiving parenteral nutrition, patients being re-fed after prolonged fasting, and dialysis patients, requires intravenous supplementation when oral repletion is not feasible. This invention provides a method and pharmaceutical composition for therapeutic administration of pyrophosphate, instead of phosphate, for phosphate or pyrophosphate repletion. During hemodialysis or peritoneal dialysis significant removal of phosphate and pyrophosphate occurs. Pyrophosphate depletion predisposes patients to vascular calcification. This invention further provides a method and pharmaceutical composition for therapeutic administration of pyrophosphate for phosphate or pyrophosphate repletion by addition of pyrophosphate to hemodialysis or peritoneal dialysis solutions.

Abstract: An apparatus for extracorporeal blood treatment has a dialysis fluid circuit and a blood circuit which are separated by a dialyzer. Arranged in the dialysis fluid circuit there is a sterile filter for producing a sterile dialysis fluid which flows into the dialyzer. To check the sterile filter, a chemical and/or physical property of the dialysis fluid, for example the conductivity, is changed upstream of the sterile filter, and the change in the property of the dialysis fluid is detected downstream of the sterile filter. From the time shift between the initiation of the conductivity impulse and the detection of the latter, it is possible to tell whether the blood treatment apparatus is fitted with a sterile filter. Moreover, the volume of the sterile filter can be inferred from the length of the time shift.

Abstract: Solutions, dialysates, and methods for measuring solutes in blood and/or for treating blood. In one aspect of the invention, a method of performing dialysis includes placing a solution in communication with blood of a subject, where a concentration of at least one electrically conductive solute in the solution, prior to being placed in communication with the blood of the subject, is substantially equal to a concentration of the at least one electrically conductive solute in the blood of the subject.

Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: The present disclosure describes novel standardized citrate replacement fluid solutions and a standardized dialysate solution for use with CRRT methods. The standardized citrate replacement fluid solutions and standardized dialysate solutions do not require modification based on the clinical status of the individual patients. The use of the standardized solutions described herein offers significant advantages over the prior art solutions used in CRRT. The present disclosure describes superior metabolic and electrolyte control and significantly increased dialyzer patency in: (a) 24 intensive care unit (ICU) patients with ARF using a 0.67% trisodium citrate replacement fluid solution, and (b) 32 ICU patients with ARF using a 0.5% trisodium citrate replacement fluid solution. Both groups were treated with Bicarbonate-25 dialysate and achieved effluent rates of 35 mL/kg/hr.

Abstract: In a device for handling blood in extracorporeal blood circulation that has at least one oxygenator, one heat exchanger, and one blood filter, the inlets and outlets in the oxygenator/heat exchanger unit are embodied such that a blood flow cross section of A?80 mm2, preferably A?120 mm2, is assured. The device can also be operated in an isolated form as a single structural part, which takes on the functions of an oxygenator and a heat exchanger with a blood filter. If a pump is provided in the device, then the pump drive can be removed as needed.

Abstract: The present invention is a peritoneal dialysis and hemodialysis hybrid-remedy planning method using an index that is shared by both peritoneal dialysis and hemodialysis and indicates an effect of dialysis. To be specific, the index is M/C(0)/VB, which is obtained by dividing a ratio M/C(0)—where M is a removal amount of a solute for a fixed time period, and C(0) is a concentration of the solute in blood before the dialysis—by a patient's body fluid volume, VB. The present invention is capable of representing the dialysis effect of PD and HD as an integrated sum, and achieving concise and explicit PD and HD hybrid-remedy planning.

Abstract: A renal treatment fluid priming method includes priming an extracorporeal circuit connected to a patient with a physiologically compatible fluid, the extracorporeal circuit including an arterial line, a venous line and blood compartment of a blood filter; and pumping from a renal treatment fluid line in communication with the blood filter (i) pulling blood from the patient through the arterial line to flush the physiologically compatible fluid through the arterial line and the blood filter compartment into the renal treatment fluid line and (ii) pulling blood from the patient through the venous line to flush the physiologically compatible fluid through the venous line and the blood filter compartment into the renal treatment fluid line, such that a greater volume of blood is pulled from the patient via (i) and (ii) than a volume of the extracorporeal circuit.

Abstract: The present invention relates to an apparatus and to a method for the determination and regulation of the concentration of at least one dissolved substance in a fluid circuit, wherein the fluid circuit comprises at least two partial circuits, and wherein the partial circuits are separated by filter in a semi-permeable manner.

Abstract: A device, system and method for exchanging components between first and second fluids by direct contact in a microfluidic channel. The fluids flow as thin layers in the channel. One of the fluids is passed through a filter upon exiting the channel and is recycled through a secondary processor which changes the fluid's properties. The recycled fluid is reused for further exchange. The filter excludes blood cells from the recycled fluid and prevents or limits clogging of the filter. The secondary processor removes metabolic waste and water by diafiltration.

Abstract: The present invention is a peritoneal dialysis and hemodialysis hybrid-remedy planning method using an index that is shared by both peritoneal dialysis and hemodialysis and indicates an effect of dialysis. To be specific, the index is M/C(0)/VB, which is obtained by dividing a ratio M/C(0)—where M is a removal amount of a solute for a fixed time period, and C(0) is a concentration of the solute in blood before the dialysis—by a patient's body fluid volume, VB. The present invention is capable of representing the dialysis effect of PD and HD as an integrated sum, achieving concise and explicit PD and HD hybrid-remedy planning.

Abstract: A device for continuously measuring osmotic pressure of blood flowing through an extracorporeal blood circuit including: a blood passage further comprising a withdrawal blood passage connectable to a blood vessel in a patient and an infusion blood passage connectable to a blood vessel in a patient; a filter further comprising a filtrate chamber, a blood chamber and a permeable membrane separating the filtrate chamber and blood chamber, wherein the blood chamber is in fluid communication with the blood passage; a pressure sensor measuring a pressure difference between the filtrate chambers and the blood chamber, and a controller receiving a pressure signal from the pressure sensor, determining an osmotic pressure across the permeable membrane of the filter, and adjusting a rate of removal of fluid from blood in the filter if the determined osmotic pressure level varies from a predetermined osmotic pressure setting.

Abstract: A medical apparatus comprises a control system allowing storage of a number of shaping profiles. Each shaping profile is stored as a plurality of pairs, including a shaping profile reference value and a time interval value. The reference value is represented as fraction, for instance a percentage, of the total weight loss the apparatus should achieve at the end of a treatment time. Each time interval value is represented either as fraction of the total treatment time or as a prefixed actual time interval. The control system calculates the actual weight loss rate versus time profile based on the desired total weight loss, on the desired total treatment time as well as on selected desired shaping profile.

Abstract: A renal failure therapy system includes a blood pump; a citrate pump; and a control unit configured to automatically control the blood pump and the citrate pump to achieve a citrate flowrate that is based on at least a blood flowrate.

Abstract: A dialysate regeneration chamber is provided. In one embodiment, the dialysate regeneration chamber may include a toxin trap configured to selectively trap toxins and repel select cations.

Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.

Abstract: A method of controlling diffusive sodium transport from the dialysate solution to the blood of a patient undergoing hemodialysis treatment or from the blood to the dialysate solution includes calculating SNa+average, an average of the patient's historic serum sodium concentrations, and estimating SNa+estimated, the patient's pre-dialysis serum sodium concentration, based on the average of the patient's measured historic pre-dialysis serum sodium concentrations, SNa+measured. The method enables adjusting DNa+, the sodium concentration of the dialysate solution, based on the average of the patient's historic serum sodium concentrations, SNa+average, if needed, and performing the dialysis treatment of the patient using a dialysate solution containing a sodium concentration DNa+.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: The invention concerns a method of collecting a biological fluid, in particular blood, with an anticoagulant and/or preservation solution added, in which the biological fluid is collected by natural flow and the anticoagulant and/or preservation solution is added by pumping, the method making provision for measuring the flow of fluid collected and slaving the pumping speed to the measured flow, so as to obtain continuously during collection a given ratio between the quantity of fluid collected and the quantity of anticoagulant and/or preservation solution added. The invention also concerns a collection machine and bag system for implementing the method.

Abstract: This disclosure generally relates to dialysis systems and related methods. In one aspect of the invention, a dialysis system includes a device configured so that a medical fluid can pass therethrough, and the device is adapted to remove one or more substances from the medical fluid as the medical fluid passes through the device. The dialysis system can also include a sodium control system adapted to alter a sodium concentration of the medical fluid.

Abstract: A stable packaged bicarbonate solution for use in dialysis treatment and for treating anemia, iron deficiency, or reducing the required dose of recombinant erythropoietin to treat anemia includes a bicarbonate solution into which ferric pyrophosphate is dissolved. The amount of ferric pyrophosphate dissolved in the bicarbonate solution is sufficient to provide a therapeutic effect for the treatment of anemia, iron deficiency or to reduce dose of recombinant erythropoietin needed to treat anemia when the bicarbonate solution is combined with other dialysis components to form a dialysate used for dialyzing a patient. The ferric pyrophosphate is stabilized in the bicarbonate solution by holding the solution in a polyolefin container or container liner, such as a high density polyethylene container or liner.

Abstract: The method according to the invention and the apparatus according to the invention are characterized in that the substitution rate Qs is modified by a predefined amount upstream or downstream of the dialyzer or filter while the flow rate QFM of the liquid withdrawn through the dialyzer membrane is modified. The blood volume RBV(t) or a variable correlated with the blood volume, e.g. the hematocrit Hct(t), is determined before and after modifying the substitution rate or the flow rate of the liquid withdrawn through the dialyzer or filter membrane in order to calculate fistula recirculation RA. In addition, the total recirculation R is determined. The percentage of fistula recirculation (RA) and/or cardiopulmonary recirculation (RCP) relative to the total recirculation is calculated from the determined fistula recirculation (RA) and the sum R of fistula recirculation (RA) and cardiopulmonary recirculation (RCP).

Abstract: An apparatus and a method for monitoring the supply of replacement fluid during an extracorporeal treatment of blood is disclosed. Detection of the supply of replacement fluid upstream or downstream of the dialyser or filter is based on a measurement of the optical or physical density of the blood or of a constituent of blood in the extracorporeal circulation. To detect pre- or post-dilution, the blood flow rate and/or the replacement rate and/or the flow rate of the fluid removed from the blood through the dialyser membrane is altered, and the density of the blood or of the constituent of blood is measured upstream and/or downstream of the dialyser. Additionally, an apparatus for treating blood with an apparatus for monitoring the supply of replacement fluid is disclosed.

Abstract: A method and apparatus for red blood collection and filtration is provided wherein a red blood cell collection assembly provides for leukoreduction filtration concurrent with or soon after the red blood cell separation and collection procedure. Such procedures involve filtering the separated red blood cells in a diluted state after and/or prior to flushing the filter with storage solution. Storage solution may thus be passed through the leukoreduction filter before, with and/or after the RBCs have been filtered therethrough. The red blood cell collection, filtration and storage assembly is preferably preconnected to a blood component separation disposable assembly, including, for example, a centrifuge vessel and a blood removal/return assembly for removing blood from a donor, passing the blood to the centrifuge vessel for separation of the blood into components for collection and providing for filtration of the separated red blood cell component.

Abstract: A method for determining online adequacy parameters for any hemodialysis, hemofiltration and hemodiafiltration treatment modality is provided. Blood equilibrated dialysate samples at the begin and/or at the end of the treatment; and a continuous measurements of waste compounds in the effluent dialysate by means of spectroscopic techniques, are required. With the data coming from the measurements and a simple mathematic approach Kt/V and reduction ratios for different compounds, which are important from the medical point of view, are obtained.

Abstract: A renal failure therapy system includes a blood pump; a citrate pump; and a control unit configured to automatically control the blood pump and the citrate pump to achieve a citrate flowrate that is based on a blood flowrate, so that the flowrates are synchronized.

Abstract: Dialysis systems comprising actuators that cooperate to perform dialysis functions and sensors that cooperate to monitor dialysis functions are disclosed. According to one aspect, such a hemodialysis system comprises a user interface model layer, a therapy layer, below the user interface model layer, and a machine layer below the therapy layer. The user interface model layer is configured to manage the state of a graphical user interface and receive inputs from a graphical user interface. The therapy layer is configured to run state machines that generate therapy commands based at least in part on the inputs from the graphical user interface. The machine layer is configured to provide commands for the actuators based on the therapy commands.

Abstract: A treatment assembly is positioned along an AV-fistula and couples therapeutic energy to an adjacent area due to a material response to an applied energy field from a remotely located energy source. The treatment assembly may be delivered into the fistula through a hemodialysis needle, or may be secured to the fistula graft itself and implanted therewith in a patient. A cover provides a shield between an anastomosis area and blood flow. Another AV-fistula includes a valved reservoir that receives a fluid agent from a hemodialysis needle while moving the needle into or from the fistula; the agent leaks from the reservoir into the fistula lumen. Another valved fistula is adjustable between an open condition and closed conditions during and between hemodialysis treatments, respectively. Another AV-fistula has a bladder reservoir coupled to a second refillable fluid reservoir and is adapted to locally deliver a therapeutic agent into the fistula lumen.